Gainers

• HCW Biologics (NASDAQ:HCWB) stock increased by 126.4% to $2.4 during Wednesday's regular session. The market value of their outstanding shares is at $7.1 million. As per the news, the Q1 earnings report came out 4 days ago.
• Silexion Therapeutics (NASDAQ:SLXN) stock rose 77.58% to $0.48. The market value of their outstanding shares is at $1.0 million. The company's, Q1 earnings came out 3 days ago.
• MetaVia (NASDAQ:MTVA) stock increased by 54.78% to $2.91. The market value of their outstanding shares is at $9.7 million. As per the press release, Q1 earnings came out 4 days ago.
• BiomX (AMEX:PHGE) stock moved upwards by 36.71% to $0.51. The market value of their outstanding shares is at $3.7 million.
• Immunovant (NASDAQ:IMVT) shares increased by 36.2% to $35.81. The market value of their outstanding shares is at $5.3 billion. As per the press release, Q4 earnings came out today.
• Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 31.26% to $3.31. The company's market cap stands at $31.5 million.

Losers

• Wellgistics Health (NASDAQ:WGRX) shares decreased by 28.6% to $0.12 during Wednesday's regular session. The market value of their outstanding shares is at $21.2 million. The company's, Q1 earnings came out yesterday.
• Sunshine Biopharma (NASDAQ:SBFM) stock decreased by 17.96% to $0.36. The market value of their outstanding shares is at $2.2 million.
• GlucoTrack (NASDAQ:GCTK) stock declined by 16.39% to $0.46. The company's market cap stands at $2.0 million. As per the press release, Q1 earnings came out 4 days ago.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) shares declined by 15.0% to $0.09.
• Lakewood-Amedex (NASDAQ:LABT) shares fell 14.61% to $0.74. The company's market cap stands at $12.4 million.
• Purple Biotech (NASDAQ:PPBT) stock declined by 12.83% to $3.06. The market value of their outstanding shares is at $3.2 million. As per the news, the Q1 earnings report came out 3 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.